ctDNA-adjusted bTMB as a predictive biomarker for patients with NSCLC treated with PD-(L)1 inhibitors

por Nie, Wei, Wang, Zhi-Jie, Zhang, Kai, Li, Bing, Cai, Yi-Ran, Wen, Feng-Cai, Zhang, Ding, Bai, Yue-Zong, Zhang, Xue-Yan, Wang, Shu-Yuan, Cheng, Lei, Zhong, Hua, Liu, Li, Wang, Jie, Han, Bao-Hui
Publicado 2022

A pilot study of neoadjuvant combination of anti-PD-1 camrelizumab and VEGFR2 inhibitor apatinib for locally advanced resectable oral squamous cell carcinoma

por Ju, Wu-tong, Xia, Rong-hui, Zhu, Dong-wang, Dou, Sheng-jin, Zhu, Guo-pei, Dong, Min-jun, Wang, Li-zhen, Sun, Qi, Zhao, Tong-chao, Zhou, Zhi-hang, Liang, Si-yuan, Huang, Ying-ying, Tang, Yong, Wu, Si-cheng, Xia, Jing, Chen, Shi-qing, Bai, Yue-zong, Li, Jiang, Zhu, Qi, Zhong, Lai-ping
Publicado 2022